TY - JOUR
T1 - Retinal photograph-based deep learning algorithms for myopia and a blockchain platform to facilitate artificial intelligence medical research
T2 - a retrospective multicohort study
AU - Tan, Tien En
AU - Anees, Ayesha
AU - Chen, Cheng
AU - Li, Shaohua
AU - Xu, Xinxing
AU - Li, Zengxiang
AU - Xiao, Zhe
AU - Yang, Yechao
AU - Lei, Xiaofeng
AU - Ang, Marcus
AU - Chia, Audrey
AU - Lee, Shu Yen
AU - Wong, Edmund Yick Mun
AU - Yeo, Ian Yew San
AU - Wong, Yee Ling
AU - Hoang, Quan V.
AU - Wang, Ya Xing
AU - Bikbov, Mukharram M.
AU - Nangia, Vinay
AU - Jonas, Jost B.
AU - Chen, Yen Po
AU - Wu, Wei Chi
AU - Ohno-Matsui, Kyoko
AU - Rim, Tyler Hyungtaek
AU - Tham, Yih Chung
AU - Goh, Rick Siow Mong
AU - Lin, Haotian
AU - Liu, Hanruo
AU - Wang, Ningli
AU - Yu, Weihong
AU - Tan, Donald Tiang Hwee
AU - Schmetterer, Leopold
AU - Cheng, Ching Yu
AU - Chen, Youxin
AU - Wong, Chee Wai
AU - Cheung, Gemmy Chui Ming
AU - Saw, Seang Mei
AU - Wong, Tien Yin
AU - Liu, Yong
AU - Ting, Daniel Shu Wei
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
PY - 2021/5
Y1 - 2021/5
N2 - Background: By 2050, almost 5 billion people globally are projected to have myopia, of whom 20% are likely to have high myopia with clinically significant risk of sight-threatening complications such as myopic macular degeneration. These are diagnoses that typically require specialist assessment or measurement with multiple unconnected pieces of equipment. Artificial intelligence (AI) approaches might be effective for risk stratification and to identify individuals at highest risk of visual loss. However, unresolved challenges for AI medical studies remain, including paucity of transparency, auditability, and traceability. Methods: In this retrospective multicohort study, we developed and tested retinal photograph-based deep learning algorithms for detection of myopic macular degeneration and high myopia, using a total of 226 686 retinal images. First we trained and internally validated the algorithms on datasets from Singapore, and then externally tested them on datasets from China, Taiwan, India, Russia, and the UK. We also compared the performance of the deep learning algorithms against six human experts in the grading of a randomly selected dataset of 400 images from the external datasets. As proof of concept, we used a blockchain-based AI platform to demonstrate the real-world application of secure data transfer, model transfer, and model testing across three sites in Singapore and China. Findings: The deep learning algorithms showed robust diagnostic performance with areas under the receiver operating characteristic curves [AUC] of 0·969 (95% CI 0·959–0·977) or higher for myopic macular degeneration and 0·913 (0·906–0·920) or higher for high myopia across the external testing datasets with available data. In the randomly selected dataset, the deep learning algorithms outperformed all six expert graders in detection of each condition (AUC of 0·978 [0·957–0·994] for myopic macular degeneration and 0·973 [0·941–0·995] for high myopia). We also successfully used blockchain technology for data transfer, model transfer, and model testing between sites and across two countries. Interpretation: Deep learning algorithms can be effective tools for risk stratification and screening of myopic macular degeneration and high myopia among the large global population with myopia. The blockchain platform developed here could potentially serve as a trusted platform for performance testing of future AI models in medicine. Funding: None.
AB - Background: By 2050, almost 5 billion people globally are projected to have myopia, of whom 20% are likely to have high myopia with clinically significant risk of sight-threatening complications such as myopic macular degeneration. These are diagnoses that typically require specialist assessment or measurement with multiple unconnected pieces of equipment. Artificial intelligence (AI) approaches might be effective for risk stratification and to identify individuals at highest risk of visual loss. However, unresolved challenges for AI medical studies remain, including paucity of transparency, auditability, and traceability. Methods: In this retrospective multicohort study, we developed and tested retinal photograph-based deep learning algorithms for detection of myopic macular degeneration and high myopia, using a total of 226 686 retinal images. First we trained and internally validated the algorithms on datasets from Singapore, and then externally tested them on datasets from China, Taiwan, India, Russia, and the UK. We also compared the performance of the deep learning algorithms against six human experts in the grading of a randomly selected dataset of 400 images from the external datasets. As proof of concept, we used a blockchain-based AI platform to demonstrate the real-world application of secure data transfer, model transfer, and model testing across three sites in Singapore and China. Findings: The deep learning algorithms showed robust diagnostic performance with areas under the receiver operating characteristic curves [AUC] of 0·969 (95% CI 0·959–0·977) or higher for myopic macular degeneration and 0·913 (0·906–0·920) or higher for high myopia across the external testing datasets with available data. In the randomly selected dataset, the deep learning algorithms outperformed all six expert graders in detection of each condition (AUC of 0·978 [0·957–0·994] for myopic macular degeneration and 0·973 [0·941–0·995] for high myopia). We also successfully used blockchain technology for data transfer, model transfer, and model testing between sites and across two countries. Interpretation: Deep learning algorithms can be effective tools for risk stratification and screening of myopic macular degeneration and high myopia among the large global population with myopia. The blockchain platform developed here could potentially serve as a trusted platform for performance testing of future AI models in medicine. Funding: None.
UR - http://www.scopus.com/inward/record.url?scp=85104341673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104341673&partnerID=8YFLogxK
U2 - 10.1016/S2589-7500(21)00055-8
DO - 10.1016/S2589-7500(21)00055-8
M3 - Article
C2 - 33890579
AN - SCOPUS:85104341673
SN - 2589-7500
VL - 3
SP - e317-e329
JO - The Lancet Digital Health
JF - The Lancet Digital Health
IS - 5
ER -